Manufacturer Name	NDC	Name of Prescription Drug	Strength
Stemline Therapeutics, Inc	72187010103	Orserdu (elacestrant)	86 mg
Stemline Therapeutics, Inc	72187010203	Orserdu (elacestrant)	345 mg

Pack Size/Volume	WAC (as of date of commercial availability)	Date of Commercial Availability
30 tablets	$7,123.00	2/3/2023
30 tablets	$21,369.00	2/3/2023

Estimated volume of patients who may be prescribed drug	Breakthrough therapy designation? (Y/N)	Priority Review? (Y/N)	Date and price of acquisition if the drug was not developed by the manufacturer else N/A
While the exact number of patients with ESR1 mutated HR+/HER2- metastatic or advanced breast cancer in the U.S. is unknown, estimates predict that up to 40% of such patients may harbor an ESR1 mutation.	N	Y	7/23/2020
While the exact number of patients with ESR1 mutated HR+/HER2- metastatic or advanced breast cancer in the U.S. is unknown, estimates predict that up to 40% of such patients may harbor an ESR1 mutation.	N	Y	7/23/2020

A description of the marketing and pricing
plans used in the launch of the new drug
When pricing Ordersu, Stemline considered
a variety of factors, including the benefit to
the patients, patient assistance programs,
reinvestment to support lifecycle
development of the compound, as well as
development of new therapies, supply chain
and other factors. Orserdu is the first oral
estrogen receptor antagonist (commonly
referred to as a SERD) and the first FDA
approved therapy for appropriate mBC
patients with ESR1 mutations.

When pricing Ordersu, Stemline considered
a variety of factors, including the benefit to
the patients, patient assistance programs,
reinvestment to support lifecycle
development of the compound, as well as
development of new therapies, supply chain
and other factors. Orserdu is the first oral
estrogen receptor antagonist (commonly
referred to as a SERD) and the first FDA
approved therapy for appropriate mBC
patients with ESR1 mutations.